Mereo BioPharma signs option-and-license deal with Sentynl for US rights to alvelestat in AATD lung disease
MREO•Financial terms and development plan
Mereo will collect a non-refundable option fee; option exercise triggers $40 million upfront and R&D payments.
The deal includes up to $435 million in milestones; Mereo also gets double-digit tiered royalties on U.S. net sales.
Mereo will lead global Phase 3 development; the program could start in early 2027, with both sides refining trial design during the option period.
Option-and-license deal for U.S. rights
Mereo BioPharma entered an option and license deal with Sentynl for alvelestat in AATD-associated lung disease, covering U.S. commercialization rights.
Sentynl secured global manufacturing rights; Mereo retained commercial rights outside the U.S. under the agreement.
